EU decision-making for marketing authorization of advanced therapy medicinal products: a case study
Open Access
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (7) , 1328-1333
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- EU marketing authorization review of orphan and non-orphan drugs does not differDrug Discovery Today, 2013
- Regulatory evaluation of Glybera in Europe — two committees, one missionNature Reviews Drug Discovery, 2013
- History of gene therapyGene, 2013
- Cell-Based Therapeutics: The Next Pillar of MedicineScience Translational Medicine, 2013
- Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industryCytotherapy, 2013
- Determinants for successful marketing authorisation of orphan medicinal products in the EUDrug Discovery Today, 2012
- Clinical Development of Advanced Therapy Medicinal Products in Europe: Evidence That Regulators Must Be ProactiveMolecular Therapy, 2012
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for CancerJAMA, 2011
- Challenges with advanced therapy medicinal products and how to meet themNature Reviews Drug Discovery, 2010
- The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcomeEuropean Journal of Clinical Pharmacology, 2002